Pyramid Biosciences
7
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Role: lead
A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream
Role: lead
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
Role: lead
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
Role: lead
A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200
Role: lead
A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants
Role: lead
A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200
Role: lead
All 7 trials loaded